75 239

Cited 0 times in

A pilot study using reflectance confocal microscopy (RCM) in the assessment of a novel formulation for the treatment of melasma.

Authors
Tsilika, K; Levy, JL; Kang, HY; Duteil, L; Khemis, A; Hughes, R; Passeron, T; Ortonne, JP; Bahadoran, P
Citation
Journal of drugs in dermatology : JDD, 10(11):1260-1264, 2011
Journal Title
Journal of drugs in dermatology : JDD
ISSN
1545-9616
Abstract
INTRODUCTION: Melasma is a common pigmentary disorder caused by abnormal melanin deposits within the skin. Hydroquinone (HQ) is presently the most popular depigmenting agent, however the treatment of melasma remains unsatisfactory, resulting in a need to evaluate new depigmenting agents.



OBJECTIVE: The objective of this study was to assess, using standard methods and a novel technique, in vivo Reflectance Confocal Microscopy (RCM), the efficacy and safety of a new non-HQ bleaching agent Dermamelan® (Mesoestetic, Barcelona, Spain) in the treatment of melasma.



METHODS: Ten women with melasma were enrolled in an open-label trial lasting four months. Patients were of Fitzpatrick skin types II-IV. A non-HQ depigmenting agent (Dermamelan) was applied once-daily for three months. Melasma Area and Severity Indices (MASI) were measured. Standard and UV-light photographs were taken and in vivo RCM, which detects pigmentary changes at a cellular level, was done. Evaluations were performed before treatment, on the first, second and third month of treatment and one month after treatment. Upon cessation of the trial, patients completed a questionnaire regarding efficacy and tolerance.



RESULTS: At baseline, RCM detected hyperpigmented keratinocytes in all patients, dendritic cells in 2/10 patients, and melanophages in 2/10 patients. Based on the MASI score, Dermamelan treatment improved melasma by 50 percent. This was confirmed by standard and UV-light photography. Maximum therapeutic effect was usually reached by one month of treatment and was maintained at one month following its completion. Interestingly Dermamelan treatment also induced a statistically significant decrease of pigmented epidermal keratinocytes as detected by RCM. Patients with melanophages on RCM at baseline had a poorer outcome, but not those with dendritic cells. Mild irritation was the only adverse event observed during treatment. The majority of patients were satisfied with the result.



CONCLUSION: This study suggests that Dermamelan produces significant rapid improvement of melasma at a clinical and cellular level and demonstrates the potential of RCM to monitor and possibly predict efficacy of a new depigmenting agent in the treatment of melasma.
MeSH terms
Dendritic Cells/metabolismDermatologic Agents/administration & dosage/adverse effects/*therapeutic useFemaleFollow-Up StudiesHumansKeratinocytes/drug effects/metabolismMelanosis/diagnosis/*drug therapyMicroscopy, Confocal/*methodsPatient SatisfactionPilot ProjectsQuestionnairesSeverity of Illness IndexTreatment Outcome
PMID
22052305
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
AJOU Authors
강, 희영
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse